Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

ObjectiveTo evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent for treating coronavirus 2019 (COVID-19).MethodsA retrospective cohort study was conducted at two general hospitals during the study period of December 2020 to May 2021. Mild COVID-19 patients with risk factors f...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ji Yeon Lee, Jee Young Lee, Jae-Hoon Ko, Miri Hyun, Hyun Ah Kim, Seongcheol Cho, Yong Dae Lee, Junghoon Song, Seunghwan Shin, Kyong Ran Peck
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	Regdanvimab monoclonal antibody COVID-19 progression outcome Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/49b7338baad74e2ebab519520a09a853
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:49b7338baad74e2ebab519520a09a853
record_format	dspace
spelling	oai:doaj.org-article:49b7338baad74e2ebab519520a09a8532021-12-01T03:00:50ZEffectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease1664-322410.3389/fimmu.2021.772320https://doaj.org/article/49b7338baad74e2ebab519520a09a8532021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.772320/fullhttps://doaj.org/toc/1664-3224ObjectiveTo evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent for treating coronavirus 2019 (COVID-19).MethodsA retrospective cohort study was conducted at two general hospitals during the study period of December 2020 to May 2021. Mild COVID-19 patients with risk factors for disease progression admitted to the hospitals within seven days of symptom onset were enrolled and followed until discharge or referral. Multivariate analyses for disease progression were conducted in the total and propensity score (PS)-matched cohorts.ResultsA total of 778 mild COVID-19 patients were included and classified as the regdanvimab (n = 234) and supportive care (n = 544) groups. Significantly fewer patients required O2 supplementation via nasal prong in the regdanvimab group (8.1%) than in the supportive care group (18.4%, P < 0.001). The decreased risk for O2 support by regdanvimab treatment was noticed in the multivariate analysis of the total cohort (HR 0.570, 95% CI 0.343–0.946, P = 0.030), but it was not statistically significant in the PS-matched cohort (P = 0.057). Progression to severe disease was also significantly lower in the regdanvimab group (2.1%) than in the supportive care group (9.6%, P < 0.001). The significantly reduced risk for progression to severe disease by regdanvimab treatment was observed in the analysis of both the total cohort (HR 0.262, 95% CI 0.103–0.667, P = 0.005) and PS-matched cohort (HR 0.176, 95% CI 0.060–0.516, P = 0.002). Potential risk factors for progression were investigated in the supportive care group and SpO2 < 97% and CRP elevation >1.5 mg/dL were common risk factors for O2 support and progression to severe disease. Among the patients with any of these factors, regdanvimab treatment was associated with decreased risk for progression to severe disease with slightly lower HR (HR 0.202, 95% CI 0.062–0.657, P = 0.008) than that of the total cohort.ConclusionRegdanvimab treatment was associated with a decreased risk of progression to severe disease.Ji Yeon LeeJee Young LeeJae-Hoon KoMiri HyunHyun Ah KimSeongcheol ChoYong Dae LeeJunghoon SongSeunghwan ShinKyong Ran PeckFrontiers Media S.A.articleRegdanvimabmonoclonal antibodyCOVID-19progressionoutcomeImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Regdanvimab monoclonal antibody COVID-19 progression outcome Immunologic diseases. Allergy RC581-607
spellingShingle	Regdanvimab monoclonal antibody COVID-19 progression outcome Immunologic diseases. Allergy RC581-607 Ji Yeon Lee Jee Young Lee Jae-Hoon Ko Miri Hyun Hyun Ah Kim Seongcheol Cho Yong Dae Lee Junghoon Song Seunghwan Shin Kyong Ran Peck Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
description	ObjectiveTo evaluate clinical effectiveness of regdanvimab, a monoclonal antibody agent for treating coronavirus 2019 (COVID-19).MethodsA retrospective cohort study was conducted at two general hospitals during the study period of December 2020 to May 2021. Mild COVID-19 patients with risk factors for disease progression admitted to the hospitals within seven days of symptom onset were enrolled and followed until discharge or referral. Multivariate analyses for disease progression were conducted in the total and propensity score (PS)-matched cohorts.ResultsA total of 778 mild COVID-19 patients were included and classified as the regdanvimab (n = 234) and supportive care (n = 544) groups. Significantly fewer patients required O2 supplementation via nasal prong in the regdanvimab group (8.1%) than in the supportive care group (18.4%, P < 0.001). The decreased risk for O2 support by regdanvimab treatment was noticed in the multivariate analysis of the total cohort (HR 0.570, 95% CI 0.343–0.946, P = 0.030), but it was not statistically significant in the PS-matched cohort (P = 0.057). Progression to severe disease was also significantly lower in the regdanvimab group (2.1%) than in the supportive care group (9.6%, P < 0.001). The significantly reduced risk for progression to severe disease by regdanvimab treatment was observed in the analysis of both the total cohort (HR 0.262, 95% CI 0.103–0.667, P = 0.005) and PS-matched cohort (HR 0.176, 95% CI 0.060–0.516, P = 0.002). Potential risk factors for progression were investigated in the supportive care group and SpO2 < 97% and CRP elevation >1.5 mg/dL were common risk factors for O2 support and progression to severe disease. Among the patients with any of these factors, regdanvimab treatment was associated with decreased risk for progression to severe disease with slightly lower HR (HR 0.202, 95% CI 0.062–0.657, P = 0.008) than that of the total cohort.ConclusionRegdanvimab treatment was associated with a decreased risk of progression to severe disease.
format	article
author	Ji Yeon Lee Jee Young Lee Jae-Hoon Ko Miri Hyun Hyun Ah Kim Seongcheol Cho Yong Dae Lee Junghoon Song Seunghwan Shin Kyong Ran Peck
author_facet	Ji Yeon Lee Jee Young Lee Jae-Hoon Ko Miri Hyun Hyun Ah Kim Seongcheol Cho Yong Dae Lee Junghoon Song Seunghwan Shin Kyong Ran Peck
author_sort	Ji Yeon Lee
title	Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
title_short	Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
title_full	Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
title_fullStr	Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
title_full_unstemmed	Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease
title_sort	effectiveness of regdanvimab treatment in high-risk covid-19 patients to prevent progression to severe disease
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/49b7338baad74e2ebab519520a09a853
work_keys_str_mv	AT jiyeonlee effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT jeeyounglee effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT jaehoonko effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT mirihyun effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT hyunahkim effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT seongcheolcho effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT yongdaelee effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT junghoonsong effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT seunghwanshin effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease AT kyongranpeck effectivenessofregdanvimabtreatmentinhighriskcovid19patientstopreventprogressiontoseveredisease
_version_	1718405900234915840

Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease

Ejemplares similares